Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genomic Research Center, |
RCV000791003 | SCV000930266 | uncertain significance | Frontotemporal dementia | 2019-04-27 | criteria provided, single submitter | clinical testing | |
Genomic Research Center, |
RCV000791004 | SCV000930267 | uncertain significance | Pick disease | 2019-04-27 | criteria provided, single submitter | clinical testing | |
Genomic Research Center, |
RCV000791005 | SCV000930268 | uncertain significance | Multiple system atrophy | 2019-04-27 | criteria provided, single submitter | clinical testing | |
Genomic Research Center, |
RCV000791006 | SCV000930269 | uncertain significance | Progressive supranuclear ophthalmoplegia | 2019-04-27 | criteria provided, single submitter | clinical testing | |
Department of Pathology and Laboratory Medicine, |
RCV001354954 | SCV001549688 | uncertain significance | not provided | no assertion criteria provided | clinical testing | The MAPT p.R222S variant was identified in the literature in a patient with early onset frontotemporal lobar degeneration who also had two PPT1 variants (Jeung_2015_PMID:29595823). The variant was identified in dbSNP (ID: rs150983093) and ClinVar (classified as uncertain significance by Genomic Research Center, Shahid Beheshti University of Medical Sciences). The variant was identified in control databases in 80 of 274120 chromosomes at a frequency of 0.0002918 (Genome Aggregation Database March 6, 2019, v2.1.1). The variant was observed in the following populations: African in 22 of 24108 chromosomes (freq: 0.000913), Other in 5 of 7046 chromosomes (freq: 0.00071), Latino in 24 of 35096 chromosomes (freq: 0.000684) and European (non-Finnish) in 29 of 123262 chromosomes (freq: 0.000235), but was not observed in the Ashkenazi Jewish, East Asian, European (Finnish), or South Asian populations. The p.R222 residue is not conserved in mammals and computational analyses (PolyPhen-2, SIFT, MutationTaster, Revel, FATHMM, MetaLR, DANN) do not suggest a high likelihood of impact to the protein; however, this information is not predictive enough to rule out pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (Splice AI exome) do not predict a difference in splicing. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance. | |
Diagnostic Laboratory, |
RCV001354954 | SCV001740683 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV001354954 | SCV001970859 | likely benign | not provided | no assertion criteria provided | clinical testing |